Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EB-1020 long-term open-label study in children and adolescents with ADHD
jRCT2071250051Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label trial of centanafadine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Number of patients experiencing treatment-emergent adverse events. Started Sep 2025; status: recruiting.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on jRCT2071250051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250051.